Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0K1ST
|
|||
Drug Name |
Revefenacin
|
|||
Synonyms |
UNII-G2AE2VE07O; G2AE2VE07O; Revefenacin [INN]; Revefenacin [WHO-DD]; Revefenacin [USAN:INN]; Revefenacin (USAN/INN); SCHEMBL356480; EX-A1722; DB11855; GSK1160724; CS-7743; GSK-1160724; HY-15851; D10978; 1211931-83-7
Click to Show/Hide
|
|||
Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Approved | [1] | |
Company |
Theravance Biopharma/Mylan
|
|||
Structure |
Download2D MOL |
|||
Formula |
C35H43N5O4
|
|||
Canonical SMILES |
CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N
|
|||
InChI |
1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)
|
|||
InChIKey |
FYDWDCIFZSGNBU-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 864750-70-9
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Muscarinic acetylcholine receptor (CHRM) | Target Info | Antagonist | [1] |
KEGG Pathway | Calcium signaling pathway | |||
cAMP signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
PI3K-Akt signaling pathway | ||||
Cholinergic synapse | ||||
Regulation of actin cytoskeleton | ||||
Pathwhiz Pathway | Muscle/Heart Contraction | |||
Reactome | Muscarinic acetylcholine receptors | |||
Acetylcholine regulates insulin secretion | ||||
G alpha (q) signalling events | ||||
WikiPathways | Monoamine GPCRs | |||
Calcium Regulation in the Cardiac Cell | ||||
Regulation of Actin Cytoskeleton | ||||
GPCRs, Class A Rhodopsin-like | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Secretion of Hydrochloric Acid in Parietal Cells | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.